Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD0754 |
Synonyms | |
Therapy Description |
AZD0754 are T-cells engineered to express a dominant negative TGF-beta type II receptor and a chimeric antigen receptor (CAR) targeting STEAP2, which potentially decrease growth of STEAP2-expressing tumors (PMID: 37966111). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD0754 | AZD-0754|AZD 0754 | AZD0754 are T-cells engineered to express a dominant negative TGF-beta type II receptor and a chimeric antigen receptor (CAR) targeting STEAP2, which potentially decrease growth of STEAP2-expressing tumors (PMID: 37966111). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06267729 | Phase Ib/II | AZD0754 | Study of AZD0754 in Participants With Metastatic Prostate Cancer (APOLLO) | Active, not recruiting | USA | AUS | 0 |